VIVES is a multi-sector fund that invests in projects with a positive societal impact
iTeos Therapeutics targets the tumor microenvironment to boost immune cell efficiency in cancer eradication.
Immunotherapy is a revolutionary approach to cancer treatment that aims to educate the...
Viridaxis is a specialist in development and supply of efficient and effective natural aphid control methods for the agricultural sector. Their R&D activities include applied field research to...
Smartnodes develops innovative control modules for dynamic outdoor lighting, delivering the right light, in the right place, at the right time. Their solutions maximize energy savings while...
Pierre Drion, business angel:
"For almost 20 years I have been passionate about what is called BioTech. This led me to invest in several companies and mainly university spin-offs. In this context, I...
Pierre Delatte, CTO and co-founder of Cissoid:
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the commercialization...
Vincent Mouret, Chairman of the Board of Cissoid:
"As Chairman of the board of Cissoid, I’ve been working closely to VIVES for the last 10 years. I have really appreciated VIVES involvement and...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to